Nasdaq:AZTA
Azenta, Inc.
A global life sciences distributor offering integrated supply chain solutions and CDMO services to accelerate pharmaceutical and biotech innovation.
Key Metrics
Investment Thesis
Bull Case
Azenta offers exposure to the secular growth of the biotech sector through its CDMO capabilities, which often command higher margins than pure distribution. The company's diverse revenue base across therapeutic areas provides a natural hedge against failures in specific drug programs or regional market shifts. Strong operating cash flow relative to net income suggests high-quality earnings quality and potential for future profitability as economies of scale are realized.
Bear Case
The company has reported consecutive years of net losses, including a significant drop in 2024, which raises concerns about underlying profitability and burn rate sustainability. Revenue contraction indicates potential weakness in the broader life sciences market or a loss of key accounts to competitors. With a retained earnings deficit of $1.42B, the balance sheet carries a substantial history of losses that investors must weigh against future growth prospects.
About Azenta, Inc.
Azenta, Inc. (AZTA) is a global life sciences solutions provider serving research institutions, contract development and manufacturing organizations (CDMOs), and healthcare providers across North America, Europe, and Asia. The company specializes in laboratory supply management, clinical trial services, and specialized chemical synthesis to support drug discovery and development. Key revenue streams include the distribution of high-quality lab materials and contract research services for biologics and small molecules.
Analysis
Management Discussion
While revenue declined to $593.8M in 2025 compared to the prior year, the company reported a net loss of $-55.8M, an improvement from the significant contraction seen in 2024. The cash flow from operations of $72.2M demonstrates strong liquidity generation despite the reported net profit deficit, largely driven by non-cash adjustments of $87.3M and positive working capital changes. The reduction in accounts receivable suggests effective collection efforts or a slowdown in credit sales volume during this period.
Industry Overview
The global life sciences supply chain industry is characterized by high fragmentation and increasing consolidation as biotech firms seek partners capable of handling complex regulatory requirements. Companies that can integrate manufacturing, clinical services, and distribution into a single platform are gaining significant market share over standalone distributors. This trend favors established players like Azenta who have the capital to invest in specialized equipment and talent.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $665.1M | $656.3M | $593.8M |
| Cost of Revenue | $401.9M | $393.0M | $323.5M |
| Gross Profit | $263.1M | $263.4M | $270.3M |
| Operating Expenses | $336.3M | $464.0M | $297.1M |
| Operating Income | $-73.1M | $-200.7M | $-26.8M |
| R&D | $34.0M | $33.5M | $30.4M |
| G&A | $316.3M | $302.7M | $261.6M |
| Stock-Based Comp | $9.4M | $14.5M | $20.9M |
| D&A | $85.6M | $90.7M | $61.2M |
| Depreciation | $37.2M | $37.5M | $32.0M |
| Amortization | $48.4M | $51.3M | $24.4M |
| Other OpEx | $-14.0M | $127.8M | $5.2M |
| Non-Operating Income | $42.7M | $33.4M | $19.7M |
| Interest Income | — | $33.2M | — |
| Pre-Tax Income | $-30.4M | $-167.3M | $-7.1M |
| Income Tax | $-17.6M | $-3.2M | $-31.6M |
| Continuing Ops | $-12.9M | $-164.2M | $24.5M |
| Discontinued Ops | $-1.4M | $0 | $-80.2M |
| Net Income | $-14.3M | $-164.2M | $-55.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.3M | $-164.2M | $-55.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.42B | $832.8M | $708.3M |
| Cash & Equivalents | $678.9M | $310.9M | $279.8M |
| Accounts Receivable | $156.5M | $172.7M | $142.2M |
| Inventory | $128.2M | $115.3M | $75.0M |
| Prepaid Expenses | $98.8M | $80.7M | $64.7M |
| Other Current Assets | $356.6M | $153.2M | $146.8M |
| Long-Term Assets | $1.47B | $1.27B | $1.35B |
| Goodwill | $784.3M | $691.4M | $702.4M |
| Operating Leases | $66.6M | $64.0M | $54.0M |
| Other LT Assets | $615.8M | $511.8M | $594.8M |
| Total Assets | $2.89B | $2.10B | $2.06B |
| Current Liabilities | $210.9M | $204.8M | $237.7M |
| Accounts Payable | $35.8M | $44.4M | $37.7M |
| Current Leases | $9.5M | $9.7M | $7.2M |
| Deferred Revenue | $34.6M | $32.0M | $31.6M |
| Taxes Payable | $7.4M | $13.3M | $9.4M |
| Other Current Liab | $123.6M | $105.4M | $151.8M |
| Long-Term Liabilities | $140.3M | $126.2M | $94.9M |
| LT Operating Leases | $60.4M | $58.8M | $51.2M |
| Other LT Liab | $79.5M | $67.0M | $43.7M |
| Total Liabilities | $351.2M | $331.1M | $332.6M |
| Shareholders' Equity | $2.53B | $1.77B | $1.73B |
| Paid-In Capital | — | $506.0M | $529.6M |
| Retained Earnings | $1.64B | $1.48B | $1.42B |
| AOCI | $-62.4M | $-13.5M | $-22.2M |
| Total L&E | $2.89B | $2.10B | $2.06B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-14.3M | $-164.2M | $-55.8M |
| Non-Cash Adjustments | $84.8M | $215.3M | $87.3M |
| Working Capital Changes | $-53.0M | $-820.0K | $40.6M |
| Cash from Operations | $17.5M | $50.3M | $72.2M |
| Capital Expenditures | $39.4M | $37.4M | $33.9M |
| Cash from Investing | $431.4M | $224.7M | $-90.5M |
| Debt Repayments | — | $0 | — |
| Share Buybacks | $838.5M | $661.7M | $0 |
| Dividends Paid | — | $0 | — |
| Cash from Financing | $-844.1M | $-659.2M | $-9.6M |
| FX Effect | $38.0M | $21.1M | $3.6M |
| Net Change in Cash | $-357.3M | $-363.1M | $-24.3M |
| Beginning Cash | $1.04B | $684.0M | $321.0M |
| Ending Cash | $684.0M | $321.0M | $296.7M |
Frequently Asked Questions
How does Azenta, Inc. make money?
The company operates primarily through two distinct segments: Laboratory Solutions, which focuses on the procurement and distribution of reagents, consumables, and equipment for academic and industrial research; and Contract Services, which includes contract development and manufacturing organizations (CDMO) providing clinical trial support, process development, and specialized synthesis for biopharmaceutical clients.
What are the main risks for AZTA?
The life sciences sector is highly susceptible to regulatory changes regarding drug approvals and manufacturing standards that could impact contract service margins. Economic downturns or reduced R&D spending by pharmaceutical giants can significantly compress demand for non-essential laboratory supplies and CDMO capacity. Rising input costs for raw materials and logistics, combined with potential increases in scientific salaries, may pressure gross margins if pricing power is insufficient.
What is AZTA's competitive advantage?
Azenta leverages a diversified portfolio spanning multiple therapeutic areas and geographic regions to mitigate cyclicality in any single market. The company possesses deep technical expertise in complex molecule synthesis and rare disease research, creating high barriers to entry against generic distributors. Its integrated supply chain platform allows for rapid scaling of clinical trial materials, offering speed-to-market advantages for biotech partners.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.